Cytokinetics is a clinical-stage biopharmaceutical company engaged in discovering and developing novel small molecule therapeutics that modulate muscle function to potentially treat serious diseases and medical conditions. The company has various drug candidates at different stages of clinical development, some in partnership with other companies, which have arisen from Cytokinetics’ muscle biology-focused research activities and are directed toward the cytoskeleton. For more information, visit the company’s Web site at www.cytokinetics.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: